Literature DB >> 1935786

Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death.

M C Pagliacci1, R Tognellini, F Grignani, I Nicoletti.   

Abstract

Somatostatin (SS) and SS analogs have been shown to exert an antiproliferative effect on several transplantable tumors in animals and to reduce the growth of pancreatic, pituitary, and mammary tumor cells in vitro. We evaluated the effects that the SS analog SMS 201-995 exerts on growth, cell-cycle parameters, and suicidal cell death (apoptosis) of human breast cancer cells (MCF-7) in vitro. SMS 201-995 significantly reduced the MCF-7 cell growth induced by serum, estradiol, insulin, and insulin-like growth Factor-I in both short term and long term experiments. The effect was maximal when 10 nM estradiol was used as mitogen in long term cultures. SMS 201-995 treatment produced a slight but transient accumulation of cells in the G2/M phase but did not cause any noteworthy reduction in the percentage of proliferating cells. There was, instead, a time-related increase in the number of cells with the flow-cytometric characteristics of apoptosis in the cultures treated with the SS analog, which correlated well with its growth-inhibiting activity. It would, therefore, seem that SMS 201-995 exerts its inhibitory effect on MCF-7 cell growth in vitro mainly by enhancing the rate of programmed (or suicidal) cell death in the culture.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1935786     DOI: 10.1210/endo-129-5-2555

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

Review 1.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

2.  Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.

Authors:  S J Reshkin; T Tedone; M Correale; A Mangia; V Casavola; A Paradiso
Journal:  Cell Prolif       Date:  1999 Apr-Jun       Impact factor: 6.831

3.  Italian Society of Endocrinology Career Award Lecture: from somatostatin to…somatomedin.

Authors:  D Ferone
Journal:  J Endocrinol Invest       Date:  2012-08-29       Impact factor: 4.256

4.  Receptor isoforms mediate opposing proliferative effects through gbetagamma-activated p38 or Akt pathways.

Authors:  L A Sellers; F Alderton; A M Carruthers; M Schindler; P P Humphrey
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

5.  Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities.

Authors:  S Inanir; M Unlü; B Okudan; E Cila; S Atik
Journal:  Eur J Nucl Med       Date:  1996-08

6.  Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins.

Authors:  E Kulig; L Jin; X Qian; E Horvath; K Kovacs; L Stefaneanu; B W Scheithauer; R V Lloyd
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

7.  Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status.

Authors:  K Nesaretnam; R Stephen; R Dils; P Darbre
Journal:  Lipids       Date:  1998-05       Impact factor: 1.880

Review 8.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

9.  Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence.

Authors:  C Liebow; D H Crean; A V Schally; T S Mang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Cellular stress and glucocorticoid hormones protect L929 mouse fibroblasts from tumor necrosis factor alpha cytotoxicity.

Authors:  M C Pagliacci; G Migliorati; M Smacchia; F Grignani; C Riccardi; I Nicoletti
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.